
Prothena (PRTA) Stock Forecast & Price Target
Prothena (PRTA) Analyst Ratings
Bulls say
Prothena Corp PLC is poised for a positive financial outlook due to the potential to earn up to $105 million in milestone payments by 2026, attributed to advancements in their partnerships with Novo Nordisk and Bristol-Myers Squibb. The company’s investigational therapeutics, including Coramitug and PRX019, show promising early results with favorable reductions in amyloid levels, despite some safety concerns. Additionally, the favorable tolerance profile of PRX012, alongside a low incidence of injection-site reactions, underscores the overall potential of Prothena's clinical pipeline in addressing significant unmet medical needs.
Bears say
Prothena Corp PLC is facing a negative outlook primarily due to its continued net losses, which are expected to persist until product approval and commercialization, likely extending through the early phases of product launch. The company's need to raise additional capital in the short term could have uncertain and potentially dilutive effects on shareholder value, hampering investor confidence. Moreover, regulatory risks present further challenges, as changes in the regulatory stance on specific diseases or molecule classes could introduce new barriers to approval and complicate the commercialization process.
This aggregate rating is based on analysts' research of Prothena and is not a guaranteed prediction by Public.com or investment advice.
Prothena (PRTA) Analyst Forecast & Price Prediction
Start investing in Prothena (PRTA)
Order type
Buy in
Order amount
Est. shares
0 shares